Hypokalaemia, or low potassium levels, can be caused by various factors. One common cause is inadequate dietary intake, where a person does not consume enough potassium-rich foods. Gastrointestinal loss, such as through diarrhoea, can also lead to hypokalaemia as the body loses potassium through the digestive system. Certain drugs, like diuretics and insulin, can affect potassium levels and contribute to hypokalaemia.

Alkalosis, a condition characterized by an imbalance in the body’s pH levels, can also cause hypokalaemia. Hypomagnesaemia, or low magnesium levels, is another potential cause. Renal artery stenosis, a narrowing of the arteries that supply blood to the kidneys, can lead to hypokalaemia as well.

Renal tubular acidosis, specifically types 1 and 2, can cause hypokalaemia. These conditions affect the kidneys’ ability to regulate acid-base balance, resulting in low potassium levels. Conn’s syndrome, Bartter’s syndrome, and Gitelman’s syndrome are all rare inherited defects that can cause hypokalaemia. Bartter’s syndrome affects the ascending limb of the loop of Henle, while Gitelman’s syndrome affects the distal convoluted tubule of the kidney.

Hypokalaemic periodic paralysis is another condition that can cause low potassium levels. Excessive ingestion of liquorice, a sweet treat made from the root of the liquorice plant, can result in hypokalaemia due to its impact on mineralocorticoid levels.

It is important to note that while type 1 and 2 renal tubular acidosis cause hypokalaemia, type 4 renal tubular acidosis actually causes hyperkalaemia, or high potassium levels.

Digoxin is eliminated through the kidneys, and if renal function is compromised, it can lead to elevated levels of digoxin and potential toxicity. To address this issue, it is necessary to decrease the patient’s digoxin dosage and closely monitor their digoxin levels and electrolyte levels.

Patients typically initiate dialysis when their glomerular filtration rate (GFR) drops to 10 ml/min. However, if the patient has diabetes, dialysis may be recommended when their GFR reaches 15 ml/min. The GFR is a measure of kidney function and indicates how well the kidneys are able to filter waste products from the blood. Dialysis is a medical procedure that helps perform the function of the kidneys by removing waste and excess fluid from the body.

Hyperkalaemia is a condition characterized by a high level of potassium in the blood, specifically a plasma potassium level greater than 5.5 mmol/l. It can be further classified into three categories based on the severity of the condition. Mild hyperkalaemia refers to a potassium level ranging from 5.5-5.9 mmol/l, while moderate hyperkalaemia is defined as a potassium level between 6.0-6.4 mmol/l. Severe hyperkalaemia is indicated by a potassium level exceeding 6.5 mmol/l.

The most common cause of hyperkalaemia in renal failure, which can occur either acutely or chronically. However, there are other factors that can contribute to this condition as well. These include acidosis, adrenal insufficiency, cell lysis, and excessive potassium intake.

Overall, hyperkalaemia is a medical condition that requires attention and management, as it can have significant implications for the body’s normal functioning.

The usual approach to managing SIADH without neurological symptoms is to restrict fluid intake. In this case, the patient has SIADH, as evidenced by low serum osmolality due to low sodium levels. It is important to note that the patient’s urine osmolality is high despite the low serum osmolality.

Further Reading:

Syndrome of inappropriate antidiuretic hormone (SIADH) is a condition characterized by low sodium levels in the blood due to excessive secretion of antidiuretic hormone (ADH). ADH, also known as arginine vasopressin (AVP), is responsible for promoting water and sodium reabsorption in the body. SIADH occurs when there is impaired free water excretion, leading to euvolemic (normal fluid volume) hypotonic hyponatremia.

There are various causes of SIADH, including malignancies such as small cell lung cancer, stomach cancer, and prostate cancer, as well as neurological conditions like stroke, subarachnoid hemorrhage, and meningitis. Infections such as tuberculosis and pneumonia, as well as certain medications like thiazide diuretics and selective serotonin reuptake inhibitors (SSRIs), can also contribute to SIADH.

The diagnostic features of SIADH include low plasma osmolality, inappropriately elevated urine osmolality, urinary sodium levels above 30 mmol/L, and euvolemic. Symptoms of hyponatremia, which is a common consequence of SIADH, include nausea, vomiting, headache, confusion, lethargy, muscle weakness, seizures, and coma.

Management of SIADH involves correcting hyponatremia slowly to avoid complications such as central pontine myelinolysis. The underlying cause of SIADH should be treated if possible, such as discontinuing causative medications. Fluid restriction is typically recommended, with a daily limit of around 1000 ml for adults. In severe cases with neurological symptoms, intravenous hypertonic saline may be used. Medications like demeclocycline, which blocks ADH receptors, or ADH receptor antagonists like tolvaptan may also be considered.

It is important to monitor serum sodium levels closely during treatment, especially if using hypertonic saline, to prevent rapid correction that can lead to central pontine myelinolysis. Osmolality abnormalities can help determine the underlying cause of hyponatremia, with increased urine osmolality indicating dehydration or renal disease, and decreased urine osmolality suggesting SIADH or overhydration.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This results in the accumulation of urea and other waste products in the body and disrupts the balance of fluids and electrolytes. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

The causes of AKI can be categorized into pre-renal, intrinsic renal, and post-renal factors. The majority of AKI cases that develop outside of healthcare settings are due to pre-renal causes, accounting for 90% of cases. These causes typically involve low blood pressure associated with conditions like sepsis and fluid depletion. Medications, particularly ACE inhibitors and NSAIDs, are also frequently implicated.

Pre-renal:
– Volume depletion (e.g., severe bleeding, excessive vomiting or diarrhea, burns)
– Oedematous states (e.g., heart failure, liver cirrhosis, nephrotic syndrome)
– Low blood pressure (e.g., cardiogenic shock, sepsis, anaphylaxis)
– Cardiovascular conditions (e.g., severe heart failure, arrhythmias)
– Renal hypoperfusion: NSAIDs, COX-2 inhibitors, ACE inhibitors or ARBs, abdominal aortic aneurysm
– Renal artery stenosis
– Hepatorenal syndrome

Intrinsic renal:
– Glomerular diseases (e.g., glomerulonephritis, thrombosis, hemolytic-uremic syndrome)
– Tubular injury: acute tubular necrosis (ATN) following prolonged lack of blood supply
– Acute interstitial nephritis due to drugs (e.g., NSAIDs), infection, or autoimmune diseases
– Vascular diseases (e.g., vasculitis, polyarteritis nodosa, thrombotic microangiopathy, cholesterol emboli, renal vein thrombosis, malignant hypertension)
– Eclampsia

Post-renal:
– Kidney stones
– Blood clot
– Papillary necrosis
– Urethral stricture
– Prostatic hypertrophy or malignancy
– Bladder tumor
– Radiation fibrosis
– Pelvic malignancy
– Retroperitoneal

Hyperkalaemia, or high levels of potassium in the blood, can be caused by various factors that are not related to drug use. These include conditions such as renal failure, where the kidneys are unable to properly regulate potassium levels, and excess potassium supplementation. Other non-drug causes include Addison’s disease, a condition characterized by adrenal insufficiency, and congenital adrenal hyperplasia. Renal tubular acidosis, specifically type 4, can also lead to hyperkalaemia. Additionally, conditions like rhabdomyolysis, burns and trauma, and tumour lysis syndrome can contribute to elevated potassium levels. Acidosis, an imbalance in the body’s pH levels, is another non-drug cause of hyperkalaemia.

On the other hand, certain medications have been associated with hyperkalaemia. These include ACE inhibitors, angiotensin receptor blockers, NSAIDs, beta-blockers, digoxin, and suxamethonium. These drugs can interfere with the body’s potassium regulation mechanisms and lead to increased levels of potassium in the blood.

In contrast, there are also conditions that result in low levels of potassium, known as hypokalaemia. Bartter’s syndrome, a rare inherited defect in the ascending limb of the loop of Henle, is characterized by hypokalaemic alkalosis and normal to low blood pressure. Type 1 and 2 renal tubular acidosis are other conditions that cause hypokalaemia. On the other hand, type 4 renal tubular acidosis leads to hyperkalaemia. Gitelman’s syndrome, another rare inherited defect, affects the distal convoluted tubule of the kidney and causes a metabolic alkalosis with hypokalaemia and hypomagnesaemia.

Lastly, excessive consumption of liquorice can result in a condition called hypermineralocorticoidism, which can lead to hypokalaemia.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This leads to the accumulation of urea and other waste products in the body, as well as disturbances in fluid balance and electrolyte levels. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

AKI is categorized into three stages based on specific criteria. In stage 1, there is a rise in creatinine levels of 26 micromol/L or more within 48 hours, or a rise of 50-99% from baseline within 7 days (1.5-1.99 times the baseline). Additionally, a urine output of less than 0.5 mL/kg/hour for more than 6 hours is indicative of stage 1 AKI.

Stage 2 AKI is characterized by a creatinine rise of 100-199% from baseline within 7 days (2.0-2.99 times the baseline), or a urine output of less than 0.5 mL/kg/hour for more than 12 hours.

In stage 3 AKI, there is a creatinine rise of 200% or more from baseline within 7 days (3.0 or more times the baseline). Alternatively, a creatinine rise to 354 micromol/L or more with an acute rise of 26 micromol/L or more within 48 hours, or a rise of 50% or more within 7 days, is indicative of stage 3 AKI. Additionally, a urine output of less than 0.3 mL/kg/hour for 24 hours or anuria (no urine output) for 12 hours also falls under stage 3 AKI.

The intravascular volume of an infant is approximately 80 ml/kg, while in older children it is around 70 ml/kg. Dehydration itself does not lead to death, but shock can. Shock can occur when there is a loss of 20 ml/kg from the intravascular space, whereas clinical dehydration is only noticeable after total losses greater than 25 ml/kg.

The table below summarizes the maintenance fluid requirements for well, normal children based on their body weight:

Bodyweight:
– First 10 kg: Daily fluid requirement of 100 ml/kg, hourly fluid requirement of 4 ml/kg
– Second 10 kg: Daily fluid requirement of 50 ml/kg, hourly fluid requirement of 2 ml/kg
– Subsequent kg: Daily fluid requirement of 20 ml/kg, hourly fluid requirement of 1 ml/kg

In general, a child showing clinical signs of dehydration without shock is assumed to be 5% dehydrated. If shock is also present, it is assumed that the child is 10% dehydrated or more. 5% dehydration means the body has lost 5 g per 100 g body weight, which is equivalent to 50 ml/kg of fluid. Therefore, 10% dehydration implies a loss of 100 ml/kg of fluid.

In this case, the child is in shock and should receive a 20 ml/kg fluid bolus. The initial volume of fluid to administer should be 20 x 25% ml = 500 ml.

Following this, the child requires:
– 100 ml/kg replacement for the 10% dehydration = 100 x 25 = 2500 ml
– 1st 10 kg = 100 ml/kg for daily maintenance fluid = 100 x 10 = 1000 ml
– 2nd 10kg = 50 ml/kg for daily maintenance fluid = 50 x 10 = 500 ml
– Subsequent kg = 20 ml/kg for daily maintenance fluid = 20 x 5 = 100 ml

The total fluid needed for rehydration and maintenance is 2500 + 1600 = 4100 ml over a 24-hour period.

The clinical features of dehydration are summarized below:

Dehydration (5%):
– Appears ‘unwell’
– Normal heart rate or tachycardia
– Normal respiratory rate or tachypnea
– Normal peripheral pulses
– Normal or mildly prolonged

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This leads to the accumulation of urea and other waste products in the body, as well as disturbances in fluid balance and electrolyte levels. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, affecting approximately 15% of adults admitted to hospitals in the UK.

AKI is categorized into three stages based on specific criteria. In stage 1, there is a rise in creatinine levels of 26 micromol/L or more within 48 hours, or a rise of 50-99% from the baseline within 7 days. Additionally, a urine output of less than 0.5 mL/kg/hour for more than 6 hours is indicative of stage 1 AKI.

Stage 2 AKI is characterized by a creatinine rise of 100-199% from the baseline within 7 days, or a urine output of less than 0.5 mL/kg/hour for more than 12 hours.

The most severe stage, stage 3 AKI, is identified by a creatinine rise of 200% or more from the baseline within 7 days. It can also be diagnosed if the creatinine level reaches 354 micromol/L or more with an acute rise of 26 micromol/L or more within 48 hours, or a rise of 50% or more within 7 days. Additionally, a urine output of less than 0.3 mL/kg/hour for 24 hours or anuria (no urine production) for 12 hours is indicative of stage 3 AKI.

Hyperkalaemia is when the level of potassium in the blood is higher than 5.5 mmol/l. It can be categorized as mild, moderate, or severe depending on the specific potassium levels. Mild hyperkalaemia is between 5.5-5.9 mmol/l, moderate hyperkalaemia is between 6.0-6.4 mmol/l, and severe hyperkalaemia is above 6.5 mmol/l. The most common cause of hyperkalaemia in renal failure, which can be acute or chronic. Other causes include acidosis, adrenal insufficiency, cell lysis, and excessive potassium intake.

Calcium is used to counteract the harmful effects of hyperkalaemia on the heart by stabilizing the cardiac cell membrane and preventing abnormal depolarization. It works quickly, usually within 15 minutes, but its effects are not long-lasting. Calcium is considered a first-line treatment for arrhythmias and significant ECG abnormalities caused by hyperkalaemia, such as widening of the QRS interval, loss of the P wave, and cardiac arrhythmias. However, arrhythmias are rare at potassium levels below 7.5 mmol/l.

It’s important to note that calcium does not lower the serum potassium level. Therefore, it should be used in conjunction with other therapies that actually help reduce potassium levels, such as insulin and salbutamol. If the pH is measured to be above 7.35 and the potassium level remains high despite nebulized salbutamol, the APLS guidelines recommend the administration of an insulin and glucose infusion.

To determine the amount of fluid that should be given to the 5-year-old child over the next 24 hours, we need to account for the following components of fluid therapy:

1. Deficit Replacement: The fluid lost due to dehydration.
2. Maintenance Fluid: The fluid needed for normal physiological needs.
3. Ongoing Losses: Any additional fluid loss (e.g., continued diarrhea or vomiting), which may need to be estimated and added if applicable.

Calculation Steps

1. Calculate the Fluid Deficit

The child is 10% dehydrated. This means that the child has lost 10% of their body weight in fluids.

• Body Weight: 20 kg
• Percentage Dehydration: 10%

Fluid Deficit=Body Weight×Percentage Dehydration

Fluid Deficit=20 kg×0.10=2 kg=2 liters=2000 ml

2. Calculate the Maintenance Fluid Requirement

Use the standard maintenance fluid calculation for children (the Holliday-Segar method):

• First 10 kg: 100 ml/kg/day
• Next 10 kg: 50 ml/kg/day

For a 20 kg child:

• First 10 kg: 10 kg×100 ml/kg/day=1000 ml/day
• Next 10 kg: 10 kg×50 ml/kg/day=500 ml/day

Total maintenance fluid requirement:

Maintenance Fluid=1000 ml+500 ml=1500 ml/day

3. Subtract the Initial Fluid Bolus

An initial fluid bolus of 20 ml/kg was given to treat shock:

• Fluid Bolus Given: 20 ml/kg×20 kg=400 ml

This amount should be subtracted from the deficit to avoid overhydration:

Remaining Deficit=2000 ml−400 ml=1600 ml

4. Total Fluid Requirement for 24 Hours

The total fluid requirement for the next 24 hours is the sum of the remaining deficit and the maintenance fluid:

Total Fluid for 24 hours=Remaining Deficit+Maintenance Fluid

Total Fluid for 24 hours=1600 ml+1500 ml=3100 ml

The intravascular volume of an infant is approximately 80 ml/kg. In older children, the intravascular volume is around 70 ml/kg.

Dehydration itself does not lead to death, but shock can. Shock can occur when there is a loss of 20 ml/kg from the intravascular space, while clinical dehydration is only noticeable after total losses of more than 25 ml/kg.

The maintenance fluid requirements for healthy, typical children are summarized in the table below:

Bodyweight:
– First 10 kg: Daily fluid requirement of 100 ml/kg, hourly fluid requirement of 4 ml/kg
– Second 10 kg: Daily fluid requirement of 50 ml/kg, hourly fluid requirement of 2 ml/kg
– Subsequent kg: Daily fluid requirement of 20 ml/kg, hourly fluid requirement of 1 ml/kg

Therefore, this child’s daily maintenance fluid requirement can be calculated as follows:

– First 10 kg: 100 ml/kg = 1000 ml
– Second 10 kg: 50 ml/kg = 500 ml
– Subsequent kg: 20 ml/kg = 40 ml

Total daily maintenance fluid requirement: 1540 ml

Hypercalcaemia, which is an elevated level of calcium in the blood, is most commonly caused by primary hyperparathyroidism and malignancy in the UK. However, there are other factors that can contribute to hypercalcaemia as well. These include an increase in dietary intake of calcium, excessive intake of vitamin D, tertiary hyperparathyroidism, overactive thyroid gland (hyperthyroidism), Addison’s disease, sarcoidosis, Paget’s disease, multiple myeloma, phaeochromocytoma, and milk-alkali syndrome. Additionally, certain medications such as lithium, thiazide diuretics, and theophyllines can also lead to hypercalcaemia. It is important to be aware of these various causes in order to properly diagnose and treat this condition.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This results in the accumulation of waste products and disturbances in fluid and electrolyte balance. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

The causes of AKI can be categorized into pre-renal, intrinsic renal, and post-renal factors. The majority of AKI cases in the community are due to pre-renal causes, accounting for 90% of cases. These are often associated with conditions such as hypotension from sepsis or fluid depletion. Medications, particularly ACE inhibitors and NSAIDs, are also frequently implicated in AKI.

The table below summarizes the most common causes of AKI:

Pre-renal:
– Volume depletion (e.g., hemorrhage, severe vomiting or diarrhea, burns)
– Oedematous states (e.g., cardiac failure, liver cirrhosis, nephrotic syndrome)
– Hypotension (e.g., cardiogenic shock, sepsis, anaphylaxis)
– Cardiovascular conditions (e.g., severe cardiac failure, arrhythmias)
– Renal hypoperfusion: NSAIDs, COX-2 inhibitors, ACE inhibitors or ARBs, Abdominal aortic aneurysm
– Renal artery stenosis
– Hepatorenal syndrome

Intrinsic renal:
– Glomerular disease (e.g., glomerulonephritis, thrombosis, hemolytic-uremic syndrome)
– Tubular injury: acute tubular necrosis (ATN) following prolonged ischemia
– Acute interstitial nephritis due to drugs (e.g., NSAIDs), infection, or autoimmune diseases
– Vascular disease (e.g., vasculitis, polyarteritis nodosa, thrombotic microangiopathy, cholesterol emboli, renal vein thrombosis, malignant hypertension)
– Eclampsia

Post-renal:
– Renal stones
– Blood clot
– Papillary necrosis
– Urethral stricture
– Prostatic hypertrophy or malignancy
– Bladder tumor
– Radiation fibrosis
– Pelvic malignancy
– Retroperitoneal fibrosis

Calcium is effective in treating hyperkalaemia by counteracting the harmful effects on the heart caused by high levels of potassium. It achieves this by stabilizing the cardiac cell membrane and preventing unwanted depolarization. The onset of action is rapid, typically within 15 minutes, but the effects do not last for a long duration. Calcium is considered the first-line treatment for severe hyperkalaemia (potassium levels above 7 mmol/l) and when significant ECG abnormalities are present, such as widened QRS interval, loss of P wave, or cardiac arrhythmias. However, if the ECG only shows peaked T waves, calcium is usually not recommended.

It is important to note that calcium does not directly affect the serum potassium levels. Therefore, when administering calcium, it should be accompanied by other therapies that actively lower the serum potassium levels, such as insulin and salbutamol.

When hyperkalaemia is accompanied by hemodynamic compromise, calcium chloride is preferred over calcium gluconate. This is because calcium chloride contains approximately three times more elemental calcium than an equal volume of calcium gluconate.

Hyperkalemia is a condition where the level of potassium in the blood is higher than normal, specifically greater than 5.5 mmol/l. It can be categorized as mild, moderate, or severe depending on the potassium level. Mild hyperkalemia is when the potassium level is between 5.5-5.9 mmol/l, moderate hyperkalemia is between 6.0-6.4 mmol/l, and severe hyperkalemia is above 6.5 mmol/l. The most common cause of hyperkalemia is renal failure, which can be acute or chronic. Other causes include acidosis, adrenal insufficiency, cell lysis, and excessive potassium intake.

In the treatment of hyperkalemia, calcium plays a crucial role. It works by counteracting the harmful effects of high potassium levels on the heart by stabilizing the cardiac cell membrane. Calcium acts quickly, with its effects seen within 15 minutes, but its effects are relatively short-lived. It is considered a first-line treatment for arrhythmias and significant ECG abnormalities caused by hyperkalemia. However, it is rare to see arrhythmias occur at potassium levels below 7.5 mmol/l.

It’s important to note that calcium does not lower the serum level of potassium. Therefore, when administering calcium, other therapies that actually help lower potassium levels, such as insulin and salbutamol, should also be used. Insulin and salbutamol are effective in reducing serum potassium levels.

When choosing between calcium chloride and calcium gluconate, calcium chloride is preferred when hyperkalemia is accompanied by hemodynamic compromise. This is because calcium chloride contains three times more elemental calcium than an equal volume of calcium gluconate.

Conn’s syndrome, also known as primary hyperaldosteronism, is often characterized by hypertension along with hypokalaemia and hypernatraemia. On the other hand, Addison’s disease typically leads to hypotension, hyponatremia, and hyperkalaemia. Hyponatraemia is commonly associated with pituitary adenoma, while acute renal failure (ARF) is characterized by elevated levels of urea and creatinine, and hyperkalaemia is frequently observed in ARF.

Further Reading:

Hyperaldosteronism is a condition characterized by excessive production of aldosterone by the adrenal glands. It can be classified into primary and secondary hyperaldosteronism. Primary hyperaldosteronism, also known as Conn’s syndrome, is typically caused by adrenal hyperplasia or adrenal tumors. Secondary hyperaldosteronism, on the other hand, is a result of high renin levels in response to reduced blood flow across the juxtaglomerular apparatus.

Aldosterone is the main mineralocorticoid steroid hormone produced by the adrenal cortex. It acts on the distal renal tubule and collecting duct of the nephron, promoting the reabsorption of sodium ions and water while secreting potassium ions.

The causes of hyperaldosteronism vary depending on whether it is primary or secondary. Primary hyperaldosteronism can be caused by adrenal adenoma, adrenal hyperplasia, adrenal carcinoma, or familial hyperaldosteronism. Secondary hyperaldosteronism can be caused by renal artery stenosis, reninoma, renal tubular acidosis, nutcracker syndrome, ectopic tumors, massive ascites, left ventricular failure, or cor pulmonale.

Clinical features of hyperaldosteronism include hypertension, hypokalemia, metabolic alkalosis, hypernatremia, polyuria, polydipsia, headaches, lethargy, muscle weakness and spasms, and numbness. It is estimated that hyperaldosteronism is present in 5-10% of patients with hypertension, and hypertension in primary hyperaldosteronism is often resistant to drug treatment.

Diagnosis of hyperaldosteronism involves various investigations, including U&Es to assess electrolyte disturbances, aldosterone-to-renin plasma ratio (ARR) as the gold standard diagnostic test, ECG to detect arrhythmia, CT/MRI scans to locate adenoma, fludrocortisone suppression test or oral salt testing to confirm primary hyperaldosteronism, genetic testing to identify familial hyperaldosteronism, and adrenal venous sampling to determine lateralization prior to surgery.

Treatment of primary hyperaldosteronism typically involves surgical adrenalectomy for patients with unilateral primary aldosteronism. Diet modification with sodium restriction and potassium supplementation may also be recommended.

Rhabdomyolysis leads to an increase in phosphate levels in the blood, which in turn causes a decrease in the levels of ionized calcium. On the other hand, conditions such as Addison’s disease, hyperthyroidism, the use of thiazide diuretics, and lithium can all contribute to an elevation in calcium levels. There are also other factors that can result in low calcium levels, including hypoparathyroidism, a deficiency of vitamin D, sepsis, fluoride poisoning, a lack of magnesium, renal failure, tumor lysis syndrome, pancreatitis, and the administration of EDTA infusions.

Generally speaking, if a child shows clinical signs of dehydration but does not exhibit shock, it can be assumed that they are 5% dehydrated. On the other hand, if shock is also present, it can be assumed that the child is 10% dehydrated or more. To put it in simpler terms, 5% dehydration means that the body has lost 5 grams of fluid per 100 grams of body weight, which is equivalent to 50 milliliters per kilogram of fluid. Similarly, 10% dehydration implies a loss of 100 milliliters per kilogram of fluid.

The clinical features of dehydration are summarized below:

Dehydration (5%):
– The child appears unwell
– The heart rate may be normal or increased (tachycardia)
– The respiratory rate may be normal or increased (tachypnea)
– Peripheral pulses are normal
– Capillary refill time (CRT) is normal or slightly prolonged
– Blood pressure is normal
– Extremities feel warm
– Decreased urine output
– Reduced skin turgor
– Sunken eyes
– Depressed fontanelle
– Dry mucous membranes

Clinical shock (10%):
– The child appears pale, lethargic, and mottled
– Tachycardia (increased heart rate)
– Tachypnea (increased respiratory rate)
– Weak peripheral pulses
– Prolonged CRT
– Hypotension (low blood pressure)
– Extremities feel cold
– Decreased urine output
– Decreased level of consciousness

Hyperkalaemia is a condition where the level of potassium in the blood is higher than normal, specifically greater than 5.5 mmol/l. It can be categorized as mild, moderate, or severe depending on the specific potassium levels. Mild hyperkalaemia is when the potassium level is between 5.5-5.9 mmol/l, moderate hyperkalaemia is between 6.0-6.4 mmol/l, and severe hyperkalaemia is when the potassium level exceeds 6.5 mmol/l. The most common cause of hyperkalaemia in renal failure, which can be either acute or chronic. Other causes include acidosis, adrenal insufficiency, cell lysis, and excessive potassium intake.

If the patient’s life is not immediately at risk due to an arrhythmia, the initial treatment for hyperkalaemia should involve the use of a beta-2 agonist, such as salbutamol (2.5-10 mg). Salbutamol activates cAMP, which stimulates the Na+/K+ ATPase pump. This action helps shift potassium into the intracellular compartment. The effects of salbutamol are rapid, typically occurring within 30 minutes. With the recommended dose, a decrease in the serum potassium level of approximately 1 mmol can be expected.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This leads to the accumulation of urea and other waste products in the body, as well as disturbances in fluid balance and electrolyte levels. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

AKI is categorized into three stages based on specific criteria. In stage 1, there is a rise in creatinine levels of 26 micromol/L or more within 48 hours, or a rise of 50-99% from baseline within 7 days (1.5-1.99 times the baseline). Additionally, a urine output of less than 0.5 mL/kg/hour for more than 6 hours is indicative of stage 1 AKI.

Stage 2 AKI is characterized by a creatinine rise of 100-199% from baseline within 7 days (2.0-2.99 times the baseline), or a urine output of less than 0.5 mL/kg/hour for more than 12 hours.

In stage 3 AKI, there is a creatinine rise of 200% or more from baseline within 7 days (3.0 or more times the baseline). Alternatively, a creatinine rise to 354 micromol/L or more with an acute rise of 26 micromol/L or more within 48 hours, or a rise of 50% or more within 7 days, is indicative of stage 3 AKI. Additionally, a urine output of less than 0.3 mL/kg/hour for 24 hours or anuria (no urine output) for 12 hours also falls under stage 3 AKI.

NSAIDs have been found to have a relatively high occurrence of renal adverse drug reactions (ADRs). These ADRs primarily occur due to changes in renal haemodynamics caused by alterations in prostaglandin levels.

Normally, prostaglandins play a role in dilating the afferent arteriole of the glomerulus. This dilation helps maintain normal glomerular perfusion and glomerular filtration rate (GFR).

However, NSAIDs work by reducing prostaglandin levels. This reduction leads to unopposed vasoconstriction of the afferent arteriole, resulting in decreased renal plasma flow. Consequently, this decrease in renal plasma flow leads to a decrease in GFR. It is important to note that NSAIDs do not have any impact on the filtration fraction itself.

All individuals diagnosed with stage 5 chronic kidney disease should be given the option to choose between haemodialysis or peritoneal dialysis. Peritoneal dialysis should be prioritized as the preferred treatment for the following groups of patients: those who still have some remaining kidney function, adult patients without major additional health conditions, and children who are two years old or younger.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This results in the accumulation of urea and other waste products in the body and disrupts the balance of fluids and electrolytes. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

The causes of AKI can be categorized into pre-renal, intrinsic renal, and post-renal factors. The majority of AKI cases that develop outside of healthcare settings are due to pre-renal causes, accounting for 90% of cases. These causes typically involve low blood pressure associated with conditions like sepsis and fluid depletion. Medications, particularly ACE inhibitors and NSAIDs, are also frequently implicated.
Pre-renal:
– Volume depletion (e.g., severe bleeding, excessive vomiting or diarrhea, burns)
– Oedematous states (e.g., heart failure, liver cirrhosis, nephrotic syndrome)
– Low blood pressure (e.g., cardiogenic shock, sepsis, anaphylaxis)
– Cardiovascular conditions (e.g., severe heart failure, arrhythmias)
– Renal hypoperfusion: NSAIDs, COX-2 inhibitors, ACE inhibitors or ARBs, abdominal aortic aneurysm
– Renal artery stenosis
– Hepatorenal syndrome

Intrinsic renal:
– Glomerular diseases (e.g., glomerulonephritis, thrombosis, hemolytic-uremic syndrome)
– Tubular injury: acute tubular necrosis (ATN) following prolonged lack of blood supply
– Acute interstitial nephritis due to drugs (e.g., NSAIDs), infection, or autoimmune diseases
– Vascular diseases (e.g., vasculitis, polyarteritis nodosa, thrombotic microangiopathy, cholesterol emboli, renal vein thrombosis, malignant hypertension)
– Eclampsia

Post-renal:
– Kidney stones
– Blood clot
– Papillary necrosis
– Urethral stricture
– Prostatic hypertrophy or malignancy
– Bladder tumor
– Radiation fibrosis
– Pelvic malignancy
– Retroperitoneal

Respiratory alkalosis can be caused by hyperventilation, such as during periods of anxiety. It can also be a result of conditions like pulmonary embolism, CNS disorders (such as stroke or encephalitis), altitude, pregnancy, or the early stages of aspirin overdose.

Respiratory acidosis is often associated with chronic obstructive pulmonary disease (COPD) or life-threatening asthma. Other causes include pulmonary edema, sedative drug overdose (such as opiates or benzodiazepines), neuromuscular disease, obesity, or certain medications.

Metabolic alkalosis can occur due to vomiting, potassium depletion (often caused by diuretic usage), Cushing’s syndrome, or Conn’s syndrome.

Metabolic acidosis with a raised anion gap can be caused by conditions like lactic acidosis (which can result from hypoxemia, shock, sepsis, or infarction) or ketoacidosis (commonly seen in diabetes, starvation, or alcohol excess). Other causes include renal failure or poisoning (such as late stages of aspirin overdose, methanol, or ethylene glycol).

Metabolic acidosis with a normal anion gap can be attributed to conditions like renal tubular acidosis, diarrhea, ammonium chloride ingestion, or adrenal insufficiency.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This results in the accumulation of waste products and disturbances in fluid and electrolyte balance. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

The causes of AKI can be categorized into pre-renal, intrinsic renal, and post-renal factors. The majority of AKI cases in the community are due to pre-renal causes, accounting for 90% of cases. These are often associated with conditions such as hypotension from sepsis or fluid depletion. Medications, particularly ACE inhibitors and NSAIDs, are also frequently implicated in AKI.

The table below summarizes the most common causes of AKI:

Pre-renal:
– Volume depletion (e.g., hemorrhage, severe vomiting or diarrhea, burns)
– Oedematous states (e.g., cardiac failure, liver cirrhosis, nephrotic syndrome)
– Hypotension (e.g., cardiogenic shock, sepsis, anaphylaxis)
– Cardiovascular conditions (e.g., severe cardiac failure, arrhythmias)
– Renal hypoperfusion: NSAIDs, COX-2 inhibitors, ACE inhibitors or ARBs, Abdominal aortic aneurysm
– Renal artery stenosis
– Hepatorenal syndrome

Intrinsic renal:
– Glomerular disease (e.g., glomerulonephritis, thrombosis, hemolytic-uremic syndrome)
– Tubular injury: acute tubular necrosis (ATN) following prolonged ischemia
– Acute interstitial nephritis due to drugs (e.g., NSAIDs), infection, or autoimmune diseases
– Vascular disease (e.g., vasculitis, polyarteritis nodosa, thrombotic microangiopathy, cholesterol emboli, renal vein thrombosis, malignant hypertension)
– Eclampsia

Post-renal:
– Renal stones
– Blood clot
– Papillary necrosis
– Urethral stricture
– Prostatic hypertrophy or malignancy
– Bladder tumor
– Radiation fibrosis
– Pelvic malignancy
– Retroperitoneal fibrosis

Generally speaking, if a child shows clinical signs of dehydration but does not exhibit shock, it can be assumed that they are 5% dehydrated. On the other hand, if shock is also present, it can be assumed that the child is 10% dehydrated or more. When we say 5% dehydration, it means that the body has lost 5 grams per 100 grams of body weight, which is equivalent to 50 milliliters per kilogram of fluid. Similarly, 10% dehydration implies a fluid loss of 100 milliliters per kilogram of fluid.

In the case of this child, they are 10% dehydrated, which means they have lost 100 milliliters per kilogram of fluid. Considering their weight of 30 kilograms, their estimated fluid loss amounts to 100 multiplied by 30, which equals 3000 milliliters.

Since this child is also in shock, they should receive a fluid bolus of 20 milliliters per kilogram. Therefore, the initial volume of fluid to administer would be 20 multiplied by 30 milliliters, resulting in 600 milliliters.

To summarize the clinical features of dehydration and shock, please refer below:

Dehydration (5%):
– The child appears unwell
– Normal heart rate or tachycardia
– Normal respiratory rate or tachypnea
– Normal peripheral pulses
– Normal or mildly prolonged capillary refill time (CRT)
– Normal blood pressure
– Warm extremities
– Decreased urine output
– Reduced skin turgor
– Sunken eyes
– Depressed fontanelle
– Dry mucous membranes

Clinical shock (10%):
– Pale, lethargic, mottled appearance
– Tachycardia
– Tachypnea
– Weak peripheral pulses
– Prolonged capillary refill time (CRT)
– Hypotension
– Cold extremities
– Decreased urine output
– Decreased level of consciousness

The intravascular volume of an infant is approximately 80 ml/kg, while in older children it is around 70 ml/kg. Dehydration itself does not lead to death, but shock can occur when there is a loss of 20 ml/kg from the intravascular space. Clinical dehydration becomes evident only after total losses greater than 25 ml/kg.

The table below summarizes the maintenance fluid requirements for well, normal children:

Bodyweight:
– First 10 kg: Daily fluid requirement of 100 ml/kg and hourly fluid requirement of 4 ml/kg.
– Second 10 kg: Daily fluid requirement of 50 ml/kg and hourly fluid requirement of 2 ml/kg.
– Subsequent kg: Daily fluid requirement of 20 ml/kg and hourly fluid requirement of 1 ml/kg.

Based on this information, the hourly maintenance fluid requirements for this child can be calculated as follows:

– First 10 kg: 4 ml/kg = 40 ml
– Second 10 kg: 2 ml/kg = 20 ml
– Subsequent kg: 1 ml/kg = 5 ml

Therefore, the total hourly maintenance fluid requirement for this child is 65 ml.

Generally speaking, if a child shows clinical signs of dehydration but does not exhibit shock, it can be assumed that they are 5% dehydrated. On the other hand, if shock is also present, it can be assumed that the child is 10% dehydrated or more. To put it in simpler terms, 5% dehydration means that the body has lost 5 grams of fluid per 100 grams of body weight, which is equivalent to 50 milliliters per kilogram of fluid. Similarly, 10% dehydration implies a loss of 100 milliliters per kilogram of fluid.

The clinical features of dehydration and shock are summarized below:

Dehydration (5%):
– The child appears unwell
– The heart rate may be normal or increased (tachycardia)
– The respiratory rate may be normal or increased (tachypnea)
– Peripheral pulses are normal
– Capillary refill time (CRT) is normal or slightly prolonged
– Blood pressure is normal
– Extremities feel warm
– Decreased urine output
– Reduced skin turgor
– Sunken eyes
– Depressed fontanelle
– Dry mucous membranes

Clinical shock (10%):
– The child appears pale, lethargic, and mottled
– Tachycardia (increased heart rate)
– Tachypnea (increased respiratory rate)
– Weak peripheral pulses
– Prolonged CRT
– Hypotension (low blood pressure)
– Extremities feel cold
– Decreased urine output
– Decreased level of consciousness

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This leads to the accumulation of urea and other waste products in the body, as well as disturbances in fluid balance and electrolyte levels. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

AKI is categorized into three stages based on specific criteria. In stage 1, there is a rise in creatinine levels of 26 micromol/L or more within 48 hours, or a rise of 50-99% from baseline within 7 days (1.5-1.99 times the baseline). Additionally, a urine output of less than 0.5 mL/kg/hour for more than 6 hours is indicative of stage 1 AKI.

Stage 2 AKI is characterized by a creatinine rise of 100-199% from baseline within 7 days (2.0-2.99 times the baseline), or a urine output of less than 0.5 mL/kg/hour for more than 12 hours.

In stage 3 AKI, there is a creatinine rise of 200% or more from baseline within 7 days (3.0 or more times the baseline). Alternatively, a creatinine rise to 354 micromol/L or more with an acute rise of 26 micromol/L or more within 48 hours, or a rise of 50% or more within 7 days, is indicative of stage 3 AKI. Additionally, a urine output of less than 0.3 mL/kg/hour for 24 hours or anuria (no urine output) for 12 hours also falls under stage 3 AKI.

Generally speaking, if a child shows clinical signs of dehydration but does not exhibit shock, it can be assumed that they are 5% dehydrated. On the other hand, if shock is also present, it can be assumed that the child is 10% dehydrated or more. When a child is 5% dehydrated, it means that their body has lost 5 grams of fluid per 100 grams of body weight, which is equivalent to 50 ml of fluid per kilogram. In the case of 10% dehydration, the body has lost 100 ml of fluid per kilogram.

For example, if a child is 10% dehydrated and weighs 30 kilograms, their estimated fluid loss would be 100 ml/kg x 30 kg = 3000 ml.

The clinical features of dehydration and shock are summarized below:

Dehydration (5%):
– The child appears unwell
– Their heart rate may be normal or increased (tachycardia)
– Their respiratory rate may be normal or increased (tachypnea)
– Peripheral pulses are normal
– Capillary refill time (CRT) is normal or slightly prolonged
– Blood pressure is normal
– Extremities feel warm
– Urine output is decreased
– Skin turgor is reduced
– Eyes may appear sunken
– The fontanelle (soft spot on the baby’s head) may be depressed
– Mucous membranes are dry

Clinical shock (10%):
– The child appears pale, lethargic, and mottled
– Heart rate is increased (tachycardia)
– Respiratory rate is increased (tachypnea)
– Peripheral pulses are weak
– Capillary refill time (CRT) is prolonged
– Blood pressure is low (hypotension)
– Extremities feel cold
– Urine output is decreased
– Level of consciousness is decreased

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This leads to the accumulation of urea and other waste products in the body, as well as disturbances in fluid balance and electrolyte levels. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

AKI is categorized into three stages based on specific criteria. In stage 1, there is a rise in creatinine levels of 26 micromol/L or more within 48 hours, or a rise of 50-99% from baseline within 7 days (1.5-1.99 times the baseline). Additionally, a urine output of less than 0.5 mL/kg/hour for more than 6 hours is indicative of stage 1 AKI.

Stage 2 AKI is characterized by a creatinine rise of 100-199% from baseline within 7 days (2.0-2.99 times the baseline), or a urine output of less than 0.5 mL/kg/hour for more than 12 hours.

In stage 3 AKI, there is a creatinine rise of 200% or more from baseline within 7 days (3.0 or more times the baseline). Alternatively, a creatinine rise to 354 micromol/L or more with an acute rise of 26 micromol/L or more within 48 hours, or a rise of 50% or more within 7 days, is indicative of stage 3 AKI. Additionally, a urine output of less than 0.3 mL/kg/hour for 24 hours or anuria (no urine output) for 12 hours also falls under stage 3 AKI.

ACE inhibitors work by inhibiting the conversion of angiotensin I to angiotensin II. As a result, the effects of angiotensin II are reduced, leading to the dilation of vascular smooth muscle and the efferent arteriole of the glomerulus. This, in turn, has several effects on renal measurements. Firstly, it causes an increase in renal plasma flow. Secondly, it leads to a decrease in filtration fraction. Lastly, it results in a decrease in glomerular filtration rate.

This patient is experiencing hyponatremia, which is characterized by low plasma osmolality and high urine osmolality, indicating syndrome of inappropriate antidiuretic hormone secretion (SIADH). One of the most common causes of SIADH is the use of SSRIs. On the other hand, lithium, sodium bicarbonate, and corticosteroids are known to cause hypernatremia. Plasma osmolality can be calculated using the formula (2 x Na) + Glucose + Urea. In this patient, the calculated osmolality is 265 mosmol/kg, which falls within the normal range of 275-295 mosmol/kg.

Further Reading:

Syndrome of inappropriate antidiuretic hormone (SIADH) is a condition characterized by low sodium levels in the blood due to excessive secretion of antidiuretic hormone (ADH). ADH, also known as arginine vasopressin (AVP), is responsible for promoting water and sodium reabsorption in the body. SIADH occurs when there is impaired free water excretion, leading to euvolemic (normal fluid volume) hypotonic hyponatremia.

There are various causes of SIADH, including malignancies such as small cell lung cancer, stomach cancer, and prostate cancer, as well as neurological conditions like stroke, subarachnoid hemorrhage, and meningitis. Infections such as tuberculosis and pneumonia, as well as certain medications like thiazide diuretics and selective serotonin reuptake inhibitors (SSRIs), can also contribute to SIADH.

The diagnostic features of SIADH include low plasma osmolality, inappropriately elevated urine osmolality, urinary sodium levels above 30 mmol/L, and euvolemic. Symptoms of hyponatremia, which is a common consequence of SIADH, include nausea, vomiting, headache, confusion, lethargy, muscle weakness, seizures, and coma.

Management of SIADH involves correcting hyponatremia slowly to avoid complications such as central pontine myelinolysis. The underlying cause of SIADH should be treated if possible, such as discontinuing causative medications. Fluid restriction is typically recommended, with a daily limit of around 1000 ml for adults. In severe cases with neurological symptoms, intravenous hypertonic saline may be used. Medications like demeclocycline, which blocks ADH receptors, or ADH receptor antagonists like tolvaptan may also be considered.

It is important to monitor serum sodium levels closely during treatment, especially if using hypertonic saline, to prevent rapid correction that can lead to central pontine myelinolysis. Osmolality abnormalities can help determine the underlying cause of hyponatremia, with increased urine osmolality indicating dehydration or renal disease, and decreased urine osmolality suggesting SIADH or overhydration.

This patient has been diagnosed with severe hyperkalemia and is showing significant ECG changes. The top priority in this situation is to protect the heart. It is recommended to administer 10 ml of 10% calcium chloride immediately over a period of 2-5 minutes. Calcium helps counteract the harmful effects of hyperkalemia on the heart by stabilizing the cardiac cell membrane and preventing unwanted depolarization.

Hyperkalemia is a commonly encountered electrolyte disorder, affecting up to 10% of hospitalized patients. It is typically caused by an increase in potassium release from cells or impaired excretion by the kidneys. The main causes of hyperkalemia include renal failure, certain medications (such as ACE inhibitors, ARBs, potassium-sparing diuretics, and NSAIDs), tissue breakdown (as seen in conditions like tumor lysis, rhabdomyolysis, and hemolysis), metabolic acidosis (often associated with renal failure or diabetic ketoacidosis), and endocrine disorders like Addison’s disease.

ECG changes that may be observed in hyperkalemia include a prolonged PR interval, peaked T-waves, widening of the QRS complex, reduced or absent P wave, sine wave pattern, AV dissociation, asystole, and bradycardia. It is important to note that the severity of ECG changes may not always correlate with the actual serum potassium levels in a patient.

The treatment approach for hyperkalemia depends on its severity. Mild hyperkalemia is defined as a potassium level of 5.5-5.9 mmol/L, moderate hyperkalemia as 6.0-6.4 mmol/L, and severe hyperkalemia as >6.5 mmol/L.

For mild hyperkalemia, the focus should be on addressing the underlying cause and preventing further increase in serum potassium levels. This may involve adjusting medications or dietary changes. If treatment is necessary, potassium exchange resins like calcium resonium can be used to remove potassium from the body.

In cases of moderate hyperkalemia, the goal is to shift potassium from the extracellular space into the cells. This can be achieved by administering insulin and glucose intravenously. Monitoring blood glucose levels is crucial in this situation. Potassium exchange resins should also be considered, and dialysis may be necessary.

Severe hyperkalemia without ECG changes requires immediate medical attention.

The intravascular volume of an infant is approximately 80 ml/kg, while in older children it is around 70 ml/kg. Dehydration itself does not lead to death, but shock can occur when there is a loss of 20 ml/kg from the intravascular space. Clinical dehydration becomes evident only after total losses greater than 25 ml/kg.

The table below summarizes the maintenance fluid requirements for well and normal children:

Bodyweight: First 10 kg
Daily fluid requirement: 100 ml/kg
Hourly fluid requirement: 4 ml/kg

Bodyweight: Second 10 kg
Daily fluid requirement: 50 ml/kg
Hourly fluid requirement: 2 ml/kg

Bodyweight: Subsequent kg
Daily fluid requirement: 20 ml/kg
Hourly fluid requirement: 1 ml/kg

For a well and normal child weighing less than 10 kg, the hourly maintenance fluid requirement is 4 ml/kg. Therefore, for this child, the hourly maintenance fluid requirement would be:

9 x 4 ml/hour = 36 ml/hour

Hyperkalaemia can be identified by certain signs, such as muscle weakness, cramps, and delayed deep tendon reflexes. Additionally, there are neurological signs that may be present, including flaccid paralysis, twitching, peripheral paresthesia, weakness, and hypo-reflexia.

Further Reading:

Vasoactive drugs can be classified into three categories: inotropes, vasopressors, and unclassified. Inotropes are drugs that alter the force of muscular contraction, particularly in the heart. They primarily stimulate adrenergic receptors and increase myocardial contractility. Commonly used inotropes include adrenaline, dobutamine, dopamine, isoprenaline, and ephedrine.

Vasopressors, on the other hand, increase systemic vascular resistance (SVR) by stimulating alpha-1 receptors, causing vasoconstriction. This leads to an increase in blood pressure. Commonly used vasopressors include norepinephrine, metaraminol, phenylephrine, and vasopressin.

Electrolytes, such as potassium, are essential for proper bodily function. Solutions containing potassium are often given to patients to prevent or treat hypokalemia (low potassium levels). However, administering too much potassium can lead to hyperkalemia (high potassium levels), which can cause dangerous arrhythmias. It is important to monitor potassium levels and administer it at a controlled rate to avoid complications.

Hyperkalemia can be caused by various factors, including excessive potassium intake, decreased renal excretion, endocrine disorders, certain medications, metabolic acidosis, tissue destruction, and massive blood transfusion. It can present with cardiovascular, respiratory, gastrointestinal, and neuromuscular symptoms. ECG changes, such as tall tented T-waves, prolonged PR interval, flat P-waves, widened QRS complex, and sine wave, are also characteristic of hyperkalemia.

In summary, vasoactive drugs can be categorized as inotropes, vasopressors, or unclassified. Inotropes increase myocardial contractility, while vasopressors increase systemic vascular resistance. Electrolytes, particularly potassium, are important for bodily function, but administering too much can lead to hyperkalemia. Monitoring potassium levels and ECG changes is crucial in managing hyperkalemia.

Bartter’s syndrome is a rare genetic defect that affects the ascending limb of the loop of Henle. This condition is characterized by low blood pressure and a hypokalemic alkalosis, which means there is a decrease in potassium levels in the blood.

Hyperkalemia, on the other hand, is defined as having a plasma potassium level greater than 5.5 mmol/L. There are various non-drug factors that can cause hyperkalemia, such as renal failure, excessive potassium supplementation, Addison’s disease (adrenal insufficiency), congenital adrenal hyperplasia, renal tubular acidosis (type 4), rhabdomyolysis, burns and trauma, and tumor lysis syndrome. Additionally, acidosis can also contribute to the development of hyperkalemia.

In addition to these non-drug causes, certain medications can also lead to hyperkalemia. These include ACE inhibitors, angiotensin receptor blockers, NSAIDs, beta-blockers, digoxin, and suxamethonium. It is important to be aware of these potential causes and to monitor potassium levels in order to prevent and manage hyperkalemia effectively.

Acute kidney injury (AKI), previously known as acute renal failure, is a sudden decline in kidney function. This results in the accumulation of urea and other waste products in the body and disrupts the balance of fluids and electrolytes. AKI can occur in individuals with previously normal kidney function or those with pre-existing kidney disease, known as acute-on-chronic kidney disease. It is a relatively common condition, with approximately 15% of adults admitted to hospitals in the UK developing AKI.

The causes of AKI can be categorized into pre-renal, intrinsic renal, and post-renal factors. The majority of AKI cases that develop outside of healthcare settings are due to pre-renal causes, accounting for 90% of cases. These causes typically involve low blood pressure associated with conditions like sepsis and fluid depletion. Medications, particularly ACE inhibitors and NSAIDs, are also frequently implicated.

Pre-renal:
– Volume depletion (e.g., severe bleeding, excessive vomiting or diarrhea, burns)
– Oedematous states (e.g., heart failure, liver cirrhosis, nephrotic syndrome)
– Low blood pressure (e.g., cardiogenic shock, sepsis, anaphylaxis)
– Cardiovascular conditions (e.g., severe heart failure, arrhythmias)
– Renal hypoperfusion: NSAIDs, COX-2 inhibitors, ACE inhibitors or ARBs, abdominal aortic aneurysm
– Renal artery stenosis
– Hepatorenal syndrome

Intrinsic renal:
– Glomerular diseases (e.g., glomerulonephritis, thrombosis, hemolytic-uremic syndrome)
– Tubular injury: acute tubular necrosis (ATN) following prolonged lack of blood supply
– Acute interstitial nephritis due to drugs (e.g., NSAIDs), infection, or autoimmune diseases
– Vascular diseases (e.g., vasculitis, polyarteritis nodosa, thrombotic microangiopathy, cholesterol emboli, renal vein thrombosis, malignant hypertension)
– Eclampsia

Post-renal:
– Kidney stones
– Blood clot
– Papillary necrosis
– Urethral stricture
– Prostatic hypertrophy or malignancy
– Bladder tumor
– Radiation fibrosis
– Pelvic malignancy
– Retroperitoneal